Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
6.52
+0.46 (7.69%)
Jun 6, 2025, 1:53 PM - Market open
Emergent BioSolutions Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 965.4 | 1,044 | 1,049 | 1,118 | 1,774 | 1,577 | Upgrade
|
| Revenue Growth (YoY) | -18.56% | -0.54% | -6.10% | -36.99% | 12.45% | 42.61% | Upgrade
|
| Cost of Revenue | 611.4 | 668.2 | 689.3 | 644.5 | 980.4 | 714.2 | Upgrade
|
| Gross Profit | 354 | 375.4 | 360 | 473 | 793.2 | 863.1 | Upgrade
|
| Selling, General & Admin | 266.6 | 298.7 | 356.7 | 339.5 | 348.7 | 304.1 | Upgrade
|
| Research & Development | 63.8 | 63.8 | 105.8 | 182.9 | - | - | Upgrade
|
| Operating Expenses | 395.6 | 427.6 | 528.1 | 582.3 | 407.2 | 363.9 | Upgrade
|
| Operating Income | -41.6 | -52.2 | -168.1 | -109.3 | 386 | 499.2 | Upgrade
|
| Interest Expense | -61.4 | -71 | -87.9 | -37.3 | -34.5 | -31.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 78.3 | 13.1 | 8.9 | -11.7 | -3.7 | 4.7 | Upgrade
|
| EBT Excluding Unusual Items | -24.7 | -110.1 | -247.1 | -158.3 | 347.8 | 472.6 | Upgrade
|
| Merger & Restructuring Charges | -56.9 | -55.9 | -33.2 | -51.4 | - | - | Upgrade
|
| Impairment of Goodwill | - | - | -218.2 | -6.7 | -41.7 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 20 | 24.3 | 74.2 | - | - | - | Upgrade
|
| Asset Writedown | - | - | -306.7 | - | - | -29 | Upgrade
|
| Other Unusual Items | -0.7 | -1.2 | -0.2 | -2.6 | -2.9 | -31.7 | Upgrade
|
| Pretax Income | -62.3 | -142.9 | -731.2 | -219 | 303.2 | 411.9 | Upgrade
|
| Income Tax Expense | 69.3 | 47.7 | 29.3 | -7.4 | 83.7 | 106.1 | Upgrade
|
| Earnings From Continuing Operations | -131.6 | -190.6 | -760.5 | -211.6 | 219.5 | 305.8 | Upgrade
|
| Net Income | -131.6 | -190.6 | -760.5 | -211.6 | 219.5 | 305.8 | Upgrade
|
| Net Income to Common | -131.6 | -190.6 | -760.5 | -211.6 | 219.5 | 305.8 | Upgrade
|
| Net Income Growth | - | - | - | - | -28.22% | 461.10% | Upgrade
|
| Shares Outstanding (Basic) | 54 | 53 | 51 | 50 | 54 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 54 | 53 | 51 | 50 | 54 | 54 | Upgrade
|
| Shares Change (YoY) | 3.58% | 3.52% | 2.20% | -7.39% | 0.56% | 2.67% | Upgrade
|
| EPS (Basic) | -2.46 | -3.60 | -14.85 | -4.22 | 4.10 | 5.80 | Upgrade
|
| EPS (Diluted) | -2.46 | -3.60 | -14.85 | -4.22 | 4.06 | 5.68 | Upgrade
|
| EPS Growth | - | - | - | - | -28.52% | 446.15% | Upgrade
|
| Free Cash Flow | 94.4 | 35.8 | -257.9 | -149.9 | 96.1 | 395 | Upgrade
|
| Free Cash Flow Per Share | 1.76 | 0.68 | -5.04 | -2.99 | 1.78 | 7.34 | Upgrade
|
| Gross Margin | 36.67% | 35.97% | 34.31% | 42.33% | 44.72% | 54.72% | Upgrade
|
| Operating Margin | -4.31% | -5.00% | -16.02% | -9.78% | 21.76% | 31.65% | Upgrade
|
| Profit Margin | -13.63% | -18.26% | -72.48% | -18.93% | 12.38% | 19.39% | Upgrade
|
| Free Cash Flow Margin | 9.78% | 3.43% | -24.58% | -13.41% | 5.42% | 25.04% | Upgrade
|
| EBITDA | 61.8 | 53.4 | -47 | 15.7 | 504.2 | 609.2 | Upgrade
|
| EBITDA Margin | 6.40% | 5.12% | -4.48% | 1.41% | 28.43% | 38.62% | Upgrade
|
| D&A For EBITDA | 103.4 | 105.6 | 121.1 | 125 | 118.2 | 110 | Upgrade
|
| EBIT | -41.6 | -52.2 | -168.1 | -109.3 | 386 | 499.2 | Upgrade
|
| EBIT Margin | -4.31% | -5.00% | -16.02% | -9.78% | 21.76% | 31.65% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 27.61% | 25.76% | Upgrade
|
| Revenue as Reported | 965.4 | 1,044 | 1,049 | 1,118 | 1,774 | 1,577 | Upgrade
|
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.